# A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation

> **NCT06068881** · PHASE2 · WITHDRAWN · sponsor: **Epizyme, Inc.**

## Conditions studied

- Follicular Lymphoma
- Refractory Follicular Lymphoma

## Interventions

- **DRUG:** Tazverik (Tazemetostat)

## Key facts

- **NCT ID:** NCT06068881
- **Lead sponsor:** Epizyme, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-09-02
- **Primary completion:** 2029-04-06
- **Final completion:** 2029-04-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Never started
- **Last updated:** 2026-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06068881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06068881, "A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06068881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*